Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
April 1, 2019 Off

ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer

By BusinessWire

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to…

April 1, 2019 Off

Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81%

By BusinessWire

Revenue growth of 2.7x compared to Fiscal 2017 Revenues SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB:…

April 1, 2019 Off

Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

By BusinessWire

-Multiple SNS-723 CAR constructs demonstrated significant expression of ASPH-specific CARs on T-cells, dose-dependent cell killing, and cytokine responses -Dose-dependent and…

April 1, 2019 Off

Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting

By BusinessWire

NEW YORK–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biotech?src=hash" target="_blank"gt;#biotechlt;/agt;–Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced…

April 1, 2019 Off

Devonian Health Group Issues Securities in Interest Settlement Due to Debenture Holders and Grants Options

By BusinessWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC–(BUSINESS WIRE)–Devonian Health Group Inc.…

Trovagene expects additional evidence of clinical efficacy of onvansertib combined with chemoterapy in Acute Myeloid Leukemia
April 1, 2019 Off

Trovagene expects additional evidence of clinical efficacy of onvansertib combined with chemoterapy in Acute Myeloid Leukemia

By Dino Mustafić

Preliminary efficacy data from Trovagene’s Phase 1b/2 study testing onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) is encouraging, in particular that it shows some complete and relatively durable responses, said lead investigator of the trial, Dr. Amer Zeidan.

April 1, 2019 Off

Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer

By BusinessWire

HONG KONG–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM) (“Aptorum”) announced today, the appointment of Dr. Thomas Wai-yip Lee as Head of…

April 1, 2019 Off

BDO USA Acquires BioProcess Technology Consultants to Expand Product Development Advisory Services in Life Sciences

By BusinessWire

WOBURN, Mass.–(BUSINESS WIRE)–BioProcess Technology Consultants Inc. (BPTC) announced today the closing of its acquisition by BDO USA, LLP, one of…

Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019
April 1, 2019 Off

Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019

By BusinessWire

First Presentation of Overall Survival Data from Post-Hoc Analysis of KEYNOTE-189 in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer…

Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018
April 1, 2019 Off

Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

By BusinessWire

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating…

Posts pagination

Previous 1 … 3,314 3,315 3,316 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine